Three Synergistic Business Development Paths

PATH ONE

Developing, licensing and commercializing cannabinoid based medications for specific medical conditions and disorders. Our drug development activities are undertaken in accordance with Food and Drug Administration (FDA) or comparable development pathways in other countries.

Our intent is that any medications we develop will be physician prescription based.

PATH TWO

The developing or licensing of proprietary delivery systems for cannabinoid-based medications. The Company’s 1st technology, XactDose, provides for the accurate dosing of cannabinoid-based medications for both humans and animals.

PATH THREE

Investments in companies, and the acquisition of technologies, or medications, focused on cannabinoid-based research, through Special Purpose Vehicles (SPV) controlled by Nexien BioPharma Inc.

Our Team

experts

Richard Greenberg

Chairman

experts

Alain Bankier

CEO & Chief Strategy Officer

experts

Robert I. Goldfarb

Chief Operating Officer

experts

Evan Wasoff CPA

Chief Financial Officer

News